Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tolerability and Pharmacokinetics of Ranolazine Following Single and Multiple Sustained-release Doses in Chinese Healthy Adult Volunteers

Tolerability and Pharmacokinetics of Ranolazine Following Single and Multiple Sustained-release... Am J Cardiovasc Drugs (2013) 13:17–25 DOI 10.1007/s40256-013-0006-7 OR IGINAL RESEARCH ARTIC L E Tolerability and Pharmacokinetics of Ranolazine Following Single and Multiple Sustained-release Doses in Chinese Healthy Adult Volunteers A Randomized, Open-label, Latin Square Design, Phase I Study • • • Qin-You Tan Huan-De Li Rong-Hua Zhu • • Qi-Zhi Zhang Jun Zhang Wen-Xing Peng Published online: 26 January 2013 Springer International Publishing Switzerland 2013 Abstract deviations [SDs]). Adverse events (AEs) were monitored Background and Objectives Ranolazine was approved by throughout the study via subject interview, vital signs, and the US Food and Drug Administration in January 2006 for blood sampling. the treatment of chronic angina pectoris, and is the first Results The LC-MS/MS method was developed and approved agent from a new class of anti-anginal drugs in validated. Twelve Chinese subjects (six men, six women) almost 25 years. The primary objective of this study was to were enrolled in the single-dose phase of the pharmaco- determine the concentration of ranolazine in human plasma kinetic study. The mean (SD) age of the subjects was 24.7 using the liquid chromatography/tandem mass spectrome- (1.6) years; their mean (SD) weight was 61.3 (6.4) kg, their try (LC-MS/MS) method and to compare http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Tolerability and Pharmacokinetics of Ranolazine Following Single and Multiple Sustained-release Doses in Chinese Healthy Adult Volunteers

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/tolerability-and-pharmacokinetics-of-ranolazine-following-single-and-OCjL7m2vyS

References (22)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-013-0006-7
pmid
23355361
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2013) 13:17–25 DOI 10.1007/s40256-013-0006-7 OR IGINAL RESEARCH ARTIC L E Tolerability and Pharmacokinetics of Ranolazine Following Single and Multiple Sustained-release Doses in Chinese Healthy Adult Volunteers A Randomized, Open-label, Latin Square Design, Phase I Study • • • Qin-You Tan Huan-De Li Rong-Hua Zhu • • Qi-Zhi Zhang Jun Zhang Wen-Xing Peng Published online: 26 January 2013 Springer International Publishing Switzerland 2013 Abstract deviations [SDs]). Adverse events (AEs) were monitored Background and Objectives Ranolazine was approved by throughout the study via subject interview, vital signs, and the US Food and Drug Administration in January 2006 for blood sampling. the treatment of chronic angina pectoris, and is the first Results The LC-MS/MS method was developed and approved agent from a new class of anti-anginal drugs in validated. Twelve Chinese subjects (six men, six women) almost 25 years. The primary objective of this study was to were enrolled in the single-dose phase of the pharmaco- determine the concentration of ranolazine in human plasma kinetic study. The mean (SD) age of the subjects was 24.7 using the liquid chromatography/tandem mass spectrome- (1.6) years; their mean (SD) weight was 61.3 (6.4) kg, their try (LC-MS/MS) method and to compare

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Jan 26, 2013

There are no references for this article.